Program
Potassium Chloride
Also written as “Custodiol”, “HalfLytely” and “PLENVU®”.
Its studies are mostly in Aortic Valve Disease · Heart Failure · Coronary Artery Disease, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dr. F. Köhler Chemie | 41 open or running | phase 3since Feb 14, 2014 | Sep 29, 2011 | Jan 2027phase 2 · NCT06032195 |
| Sebela Pharmaceuticals | 30 open or running | phase 4since Sep 9, 2005 | Sep 9, 2005 | none ahead |
| Norgine | 11 open or running | phase 3since Oct 16, 2025 | Oct 16, 2025 | Jan 6, 2027phase 3 · NCT07218523 |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 9, 2005First study: phase 4 study in ColonoscopyNew to Sebela PharmaceuticalsSebela Pharmaceuticals · NCT00164177 · 20 enrolled · United States
- Sep 9, 20052 phase 3 studies in ColonoscopySebela Pharmaceuticals · NCT00164164, NCT00164151
- Sep 29, 2011Dr. F. Köhler Chemie's first study: phase 2 study in Coronary Artery DiseaseNew to Dr. F. Köhler ChemieDr. F. Köhler Chemie · NCT01444235 · 102 enrolled · Germany
- Feb 14, 2014Phase 3 study in Aortic Valve DiseaseDr. F. Köhler Chemie · NCT02098772 · 530 enrolled · Germany
- Aug 11, 2015Phase 3 study in Heart FailureDr. F. Köhler Chemie · NCT02869022 · 105 enrolled · Austria, Germany
- Aug 21, 2023Phase 2 study in Heart TransplantationDr. F. Köhler Chemie · NCT06032195 · 15 planned · Germany
- Oct 16, 2025Norgine's first study: phase 3 study in Bowel Cleansing Prior to Clinical ProceduresNew to NorgineNorgine · NCT07218523 · 212 planned · Belgium, Croatia, Germany and more
Ahead
- Jan 2027Primary completion: phase 2 study in Heart TransplantationDr. F. Köhler Chemie · NCT06032195
- Jan 6, 2027Primary completion: phase 3 study in Bowel Cleansing Prior to Clinical ProceduresNorgine · NCT07218523
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07218523Bowel Cleansing Prior to Clinical Procedures · Belgium, Croatia, Germany and more | 3 | Recruiting | Norgine | Jan 6, 2027 | 212 |
| NCT06032195Heart Transplantation · Germany | 2 | Recruiting | Dr. F. Köhler Chemie | Jan 2027 | 15 |
| NCT02869022Heart Failure · Austria, Germany | 3 | Completed | Dr. F. Köhler Chemie | Sep 2, 2019 | 105 |
| NCT02098772Aortic Valve Disease · Germany | 3 | Completed | Dr. F. Köhler Chemie | Nov 16, 2018 | 530 |
| NCT01444235Coronary Artery Disease · Germany | 2 | Completed | Dr. F. Köhler Chemie | May 2012 | 102 |
| NCT00164177Colonoscopy · United States | 4 | Completed | Sebela Pharmaceuticals | Dec 2004 | 20 |
| NCT00164164Colonoscopy · United States | 3 | Completed | Sebela Pharmaceuticals | Jun 2000 | 200 |
| NCT00164151Colonoscopy · United States | 3 | Completed | Sebela Pharmaceuticals | May 2002 | 60 |
How it is read
Names in the registry
- “Custodiol”, 4 entries
- “HalfLytely”, 3 entries
- “PLENVU®”, 1 entry
Conditions, from the studies’ own filings
- Aortic Valve Disease, 1 study
- Heart Failure, 1 study
- Coronary Artery Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.